Hepatitis News

FDA Breakthrough Therapy Designation Awarded for AbbVie’s Investigational HCV Regimen

Posted on
Health Medical Breakthroughs Treatment

(PR Newswire) AbbVie recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C virus (HCV) who failed previous therapy with direct-acting antivirals (DAAs) in genotype 1 (GT1), including therapy with […]